Diagnosing Systemic Lupus Erythematosus

Initial Screening Approach

The European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) recommend diagnosing SLE by first screening with ANA testing (using 1:160 dilution cutoff in unselected populations), then confirming with anti-dsDNA antibodies and clinical criteria requiring involvement of at least two organ systems, with final classification requiring fulfillment of the EULAR/ACR 2019 criteria 1, 2
Use a 1:160 dilution as the cutoff point for ANA detection in unselected populations to avoid false positives 1

When ANA is positive, proceed with comprehensive autoantibody testing including anti-dsDNA antibodies (use double-screening strategy: last-generation solid phase assay first, then Crithidia luciliae immunofluorescence test for confirmation) 1
Measure C3 and C4 complement levels at baseline, as low complement combined with positive anti-dsDNA strongly supports active SLE 1, 2, 3

Evaluate for specific manifestations across multiple systems, including skin, musculoskeletal, renal, hematologic, neuropsychiatric, and cardiopulmonary systems 2, 3
Order baseline laboratory tests, including complete blood count, serum creatinine and albumin, urinalysis with microscopy, erythrocyte sedimentation rate, and C-reactive protein 2, 3

Apply EULAR/ACR 2019 criteria as the standard for classification 1
Perform renal biopsy when lupus nephritis is suspected to confirm diagnosis, assess disease activity versus chronicity, and guide immunosuppressive therapy 4
Skin biopsy is mandatory for histological confirmation when cutaneous lesions are present 3

Use validated activity indices (SLEDAI, BILAG, or SLE-DAS) to monitor lupus activity and detect flares 2
Repeat anti-dsDNA and complement levels at follow-up visits even if previously negative/normal 1
Monitor every 6-12 months with CBC, ESR, CRP, serum albumin, creatinine, urinalysis, anti-dsDNA, C3, and C4 levels 3
Patients with anti-C1q antibodies have nearly 100% prevalence during active lupus nephritis and critical negative predictive value (absence makes flare-up doubtful) 1
Persistent anti-dsDNA antibodies and hypocomplementemia after treatment indicate high risk for renal relapse 4